Abstract

Electropathy/Electrohomoeopathy is a comparatively modern medical technique that falls under the genre of complementary and alternative medicine. This medical technique was discovered in Italy in 1865 by Count Ceaser Mattei. Its drugs are composed entirely of herbal/medicinal plants and are manufactured with purified water and a sophisticated process of extracting spagiric essence from medicinal plants at room temperature. Uterine fibroids are noncancerous uterine growths that commonly arise during childbearing year. Uterine fibroids, also known as leiomyomas (lie-o-my-O-muhs) or myomas, aren't linked to an increased risk of uterine cancer and almost never turn cancerous. Fibroids range in size from microscopic seedlings that are undetectable to large masses that deform and expand the uterus. A single fibroid or a group of them can be present. Multiple fibroids can cause the uterus to enlarge to the point where it reaches the rib cage, causing weight gain. Uterine fibroids affect many women at some point in their life. However, because uterine fibroids rarely cause symptoms, people may be unaware that they have them. During a pelvic exam or a pregnancy ultrasound, fibroids may be encounter by chance. By the time they reach at the age 50, 20% to 80% of women experience fibroids. Women in their age forties and early fifties are the most susceptible to develop get fibroids. In this article we are going to discussed effectiveness of Electrohomoeopathy medicine on Uterine fibroids. How a new medical science which is totally plants-based source cost effective and accelerating its mechanism of action due to specialization of its unique fundamental principal and philosophy and satisfaction of patient due to the extraordinary result of Electrohomoeopathy medicine.

References

1. W. Bowden, J. Skorupski, E. Kovanci, and A. Rajkovic, “Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays,” Molecular Human Reproduction, vol. 15, no. 9, pp. 563–568, 2009.
2. S. K. Laughlin, J. C. Schroeder, and D. D. Baird, “New directions in the epidemiology of uterine fibroids,” Seminars in Reproductive Medicine, vol. 28, no. 3, pp. 204–217, 2010.
3. S. F. Cramer and A. Patel, “The frequency of uterine leiomyomas,” American Journal of Clinical Pathology, vol. 94, no. 4, pp. 435–438, 1990.
4. M. Payson, P. Leppert, and J. Segars, “Epidemiology of myomas,” Obstetrics and Gynecology Clinics of North America, vol. 33, no. 1, pp. 1–11, 2006.
5. Lauren A. Wise*† and Shannon K. Laughlin-Tommaso Epidemiology of Uterine Fibroids From Menarche to Menopause Clin Obstet Gynecol. 2016 Mar; 59(1): 2–24.
6. S. D. Peddada, S. K. Laughlin, K. Miner et al., “Growth of uterine leiomyomata among premenopausal black and white women,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19887–19892, 2008. (6)
7. T. Wang, X. Zhang, L. Obijuru et al., “A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas,” Genes Chromosomes and Cancer, vol. 46, no. 4, pp. 336–347, 2007. (7)
8. K. H. Kjerulff, P. Langenberg, J. D. Seidman, P. D. Stolley, and G. M. Guzinski, “Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 41, no. 7, pp. 483–490, 1996. (8)
9. G. P. Flake, J. Andersen, and D. Dixon, “Etiology and pathogenesis of uterine leiomyomas: a review,” Environmental Health Perspectives, vol. 111, no. 8, pp. 1037–1054, 2003. (9)
10. M. Sabry, S. K. Halder, A. S. Allah, E. Roshdy, V. Rajaratnam, and A. Al-Hendy, “Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study,” International Journal of Women's Health, vol. 5, pp. 93–100, 2013. (10)
11. M. Sabry, S. K. Halder, A. S. Allah, E. Roshdy, V. Rajaratnam, and A. Al-Hendy, “Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study,” International Journal of Women's Health, vol. 5, pp. 93–100, 2013. (11)
12. E. M. Vikhlyaeva, “Familial predisposition to uterine leiomyomas,” International Journal of Gynecology and Obstetrics, vol. 51, no. 2, pp. 127–131, 1995. (12)
13. T. M. Saldana, M. Moshesh, and D. D. Baird, “Self-reported family history of leiomyoma: not a reliable marker of high risk,” Annals of Epidemiology, vol. 23, no. 5, pp. 286–290, 2013. (13)
14. G. P. Flake, J. Andersen, and D. Dixon, “Etiology and pathogenesis of uterine leiomyomas: a review,” Environmental Health Perspectives, vol. 111, no. 8, pp. 1037–1054, 2003. (14)
15. G. P. Flake, J. Andersen, and D. Dixon, “Etiology and pathogenesis of uterine leiomyomas: a review,” Environmental Health Perspectives, vol. 111, no. 8, pp. 1037–1054, 2003. (15)
16. S. A. Shikora, J. M. Niloff, B. R. Bistrian, R. A. Forse, and G. L. Blackburn, “Relationship between obesity and uterine leiomyomata,” Nutrition, vol. 7, no. 4, pp. 251–255, 1991. (16)
17. S. Nair and A. Al-Hendy, “Adipocytes enhance the proliferation of human leiomyoma cells via TNF-α proinflammatory cytokine,” Reproductive Sciences, vol. 18, no. 12, pp. 1186–1192, 2011. (17)
18. G. Wyshak, R. E. Frisch, and N. L. Albright, “Lower prevalence of benign diseases of the breast and benign tumours of the reproductive system among former college athletes compared to non-athletes,” British Journal of Cancer, vol. 54, no. 5, pp. 841–845, 1986. (18)
19. M. Daniel, A. D. Martin, and D. T. Drinkwater, “Cigarette smoking, steroid hormones, and bone mineral density in young women,” Calcified Tissue International, vol. 50, no. 4, pp. 300–305, 1992. (19)
20. A. J. Tiltman, “The effect of progestins on the mitotic activity of uterine fibromyomas,” International Journal of Gynecological Pathology, vol. 4, no. 2, pp. 89–96, 1985. (20)
21. D. D. Baird and D. B. Dunson, “Why is parity protective for uterine fibroids?” Epidemiology, vol. 14, no. 2, pp. 247–250, 2003. (21)
22. S. Palomba, T. Sena, M. Morelli, R. Noia, F. Zullo, and P. Mastrantonio, “Effect of different doses of progestin on uterine leiomyomas in postmenopausal women,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 102, no. 2, pp. 199–201, 2002. (22)
23. D. W. Cramer, “Epidemiology of myomas,” Seminars in Reproductive Endocrinology, vol. 10, no. 4, pp. 320–324, 1992. (23)
24. P. A. Richards and A. J. Tiltman, “Anatomical variation of the oestrogen receptor in the non-neoplastic myometrium of fibromyomatous uteri,” Virchows Archiv, vol. 428, no. 6, pp. 347–351, 1996. (24)
25. K. L. Gross and C. C. Morton, “Genetics and the development of fibroids,” Clinical Obstetrics and Gynecology, vol. 44, pp. 335–349, 2001. (25)
26. E. A. Kogan, V. E. Ignatova, T. N. Rukhadze, E. A. Kudrina, and A. I. Ischenko, “A role of growth factors in development of various histological types of uterine leiomyoma,” Arkhiv Patologii, vol. 67, no. 3, pp. 34–38, 2005.(26)
27. J. M. Norian, M. Malik, C. Y. Parker et al., “Transforming Growth Factor β3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas,” Reproductive Sciences, vol. 16, no. 12, pp. 1153–1164, 2009. (27)
28. M. Malik, J. Webb, and W. H. Catherino, “Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells,” Clinical Endocrinology, vol. 69, no. 3, pp. 462–470, 2008. (28)
29. K. A. Kovács, A. Oszter, P. M. Göcze, J. L. Környei, and I. Szabó, “Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium,” Molecular Human Reproduction, vol. 7, no. 11, pp. 1085–1091, 2001.